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The tripartite motif (TRIM) protein, TRIM5α, restricts some retroviruses, including human immunodeficiency virus (HIV-1), from infecting
the cells of particular species. TRIM proteins contain RING, B-box, coiled-coil and, in some cases, B30.2(SPRY) domains. We investigated the
properties of human TRIM family members closely related to TRIM5. These TRIM proteins, like TRIM5α, assembled into homotrimers and co-
localized in the cytoplasm with TRIM5α. TRIM5α turned over more rapidly than related TRIM proteins. TRIM5α, TRIM34 and TRIM6
associated with HIV-1 capsid–nucleocapsid complexes assembled in vitro; the TRIM5α and TRIM34 interactions with these complexes were
dependent on their B30.2(SPRY) domains. Only TRIM5α potently restricted infection by the retroviruses studied; overexpression of TRIM34
resulted in modest inhibition of simian immunodeficiency virus (SIVmac) infection. In contrast to the other TRIM genes examined, TRIM5
exhibited evidence of positive selection. The unique features of TRIM5α among its TRIM relatives underscore its special status as an antiviral
factor.
© 2006 Elsevier Inc. All rights reserved.Keywords: Tripartite motif; Restriction factor; Retrovirus; Nonsynonymous/synonymous; Positive selection; Capsid binding; B30.2(SPRY) domain; RING; RBCCIntroduction
Retroviruses encounter dominant post-entry restrictions in
the cells of particular species. Human immunodeficiency virus
type 1 (HIV-1) infection is blocked in the cells of Old World
monkeys, whereas simian immunodeficiency virus (SIVmac)
infection is blocked in most New World monkey cells
(Himathongkham and Luciw, 1996; Hofmann et al., 1999;
Shibata et al., 1995). These restrictions are mediated by a host
protein, TRIM5α, that exhibits species-specific variation in
primates (Besnier et al., 2002; Bieniasz, 2003; Hatziioannou et
al., 2003; Stremlau et al., 2004; Song et al., 2005b, 2005c;⁎ Corresponding author. Dana-Farber Cancer Institute, 44 Binney Street-JFB
824, Boston, MA 02115, USA. Fax: +1 671 632 4338.
E-mail address: joseph_sodroski@dfci.harvard.edu (J. Sodroski).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.10.035Stoye, 2002). Human TRIM5α also accounts for the N-tropic
murine leukemia virus (N-MLV)-blocking activity found in
human cells (Hatziioannou et al., 2004b; Yap et al., 2004;
Perron et al., 2004; Keckesova et al., 2004). The viral
determinant of susceptibility to TRIM5α-mediated restriction
is the capsid protein (Cowan et al., 2002; Hatziioannou et al.,
2004a; Kootstra et al., 2003; Owens et al., 2003, 2004; Towers
et al., 2000).
TRIM5α is a member of the large family of tripartite motif
proteins (TRIM) (Reymond et al., 2001). Members of this
family contain RING, B-box and coiled-coil domains and thus
are also called RBCC proteins (Reymond et al., 2001). The C-
terminal portions of these proteins are more variable due to
differential splicing of the primary RNA transcript. The alpha
isoforms of many cytoplasmic TRIM proteins, like TRIM5α,
contain a B30.2 or SPRY domain. To date, more than 60 TRIM
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logues exist in other species as well. TRIM proteins arose with
the metazoans and have expanded in number during vertebrate
evolution (Reymond et al., 2001). Although many members of
the TRIM protein family have been linked to diverse biological
processes, such as transcriptional regulation, apoptosis, inflam-
mation, cell polarity determination, and antiviral activities,
none of them have been well characterized in terms of their
precise molecular and cellular functions (Jensen et al., 2001;
Saurin et al., 1996).
Besides TRIM5α, a few other TRIM proteins have been
reported to exhibit antiviral activities. TRIM1 from African
green monkey, human and owl monkey cells weakly restricts
N-MLV, but not HIV-1, infection (Yap et al., 2004).
Overexpression of TRIM19 confers resistance to vesicular
stomatitis virus (VSV) (a rhabdovirus) and influenza A virus
(an orthomyxovirus), but not encephalomyocarditis virus (a
picornavirus) (Chelbi-Alix et al., 1998). Recently, TRIM19 has
been implicated in cellular resistance to human cytomegalo-
virus and herpes simplex type 1 (Tavalai et al., 2006; Everett
et al., 2006). TRIM32 specifically binds to the activation
domain of Tat proteins from HIV-1, HIV-2 and EIAV with
high affinity, suggesting a potential role in transcription
regulation of the viral genome (Fridell et al., 1995). TRIM22
has been reported to attenuate transcription directed by the
long terminal repeat of HIV-1 in transfected cells (Tissot and
Mechti, 1995). Many TRIM proteins, including TRIM19,
TRIM21, TRIM22, TRIM34, and TRIM5α itself, can be up-
regulated by interferon, supporting their potential role as
effectors in the anti-viral cellular response (Asaoka et al.,
2005; Chelbi-Alix et al., 1995; Gongora et al., 2000; Orimo et
al., 2000; Tissot and Mechti, 1995). Thus, it has been
speculated that the TRIM proteins may represent a new family
of antiviral molecules involved in innate immunity (Nisole et
al., 2005).
In humans, the TRIM5 gene is located in a paralogous
cluster on chromosome 11 with TRIM6, TRIM34 and TRIM22.
Although TRIM6 and TRIM34 have orthologs in mammalian
genomes sequenced to date, orthologs of TRIM5 have been
unambiguously identified only in primates. TRIM12 and
TRIM30 in rodents and a cluster of ungulate TRIM proteins
are phylogenetically related to TRIM5/6/34/22 (Si et al., 2006).
One of these ungulate proteins, cow 505265, restricts the
infection of several retroviruses (Si et al., 2006; Ylinen et al.,
2006). TRIM5 and 505265 exhibit evidence of positive
selection, particularly in the exons that encode the B30.2
domain (Sawyer et al., 2005; Song et al., 2005b; Si et al.,
2006). Thus, in at least two mammalian lineages, proteins from
the same subfamily of TRIM proteins exhibit antiretroviral
activity.
In this study, we investigate the properties and antiviral
activities of six human TRIM family members, including
those closely related to TRIM5α. Only TRIM5α exhibited
potent antiretroviral activity, although TRIM34 weakly
inhibited a simian immunodeficiency virus. TRIM5α was
found to be unique in other biochemical and genetic properties
as well.Results
Sequence comparison of human TRIM family proteins
The TRIM proteins appeared with the metazoans, and
increased in number along with the evolution of vertebrates
(Reymond et al., 2001). TRIM proteins are found in the
nucleus as well as the cytoplasm. Many cytoplasmic TRIM
proteins have a carboxy-terminal B30.2(SPRY) domain. Fig. 1
shows the phylogenetic relationship of human TRIM proteins
that have B30.2(SPRY) domains. Because the B30.2(SPRY)
domains of some TRIM proteins have been subjected to strong
positive selection (Sawyer et al., 2005; Si et al., 2006; Song et
al., 2005b), additional analyses were performed after removing
the B30.2(SPRY) domain, thus reducing the possibility of
highly variable or convergent residues affecting the phyloge-
netic reconstruction (Supplementary Figure 1). The analyses of
the complete TRIM proteins and the B30.2(SPRY)-deleted
TRIM proteins yielded similar results. TRIM6, TRIM34, and
TRIM22 formed a clade with TRIM5, consistent with these
proteins being paralogs. TRIM21 is the next closest human
relative. The amino acid sequence identity of this subset of
TRIM proteins ranges from 40 to 57%. Although TRIM5,
TRIM6, TRIM22 and TRIM34 are clearly monophyletic, more
detailed phylogenetic relationships among these proteins
cannot be confidently deduced from these data alone. TRIM6,
TRIM34, TRIM22 and TRIM5 form a cluster on human
chromosome 11p15. Additional clusters of TRIM paralogs are
found on human chromosomes 5, 6 and 17; the TRIM cluster
on chromosome 6 is near the major histocompatibility complex
locus.
Colocalization of several TRIM proteins with TRIM5α
A previous study (Reymond et al., 2001) suggested that
many TRIM proteins form discrete bodies or speckles in the
cytoplasm or nucleus of overexpressing cells. TRIM5α
proteins from several primate species exhibit diffuse cytoplas-
mic staining as well as being incorporated into cytoplasmic
bodies (Song et al., 2005a). These cytoplasmic bodies have
been shown to represent pre-aggresomal structures (Diaz-
Griffero et al., 2006a). To determine whether other cytoplasmic
TRIM proteins also localize in similar structures, selected
TRIM proteins were coexpressed with a V5-tagged rhesus
monkey TRIM5α in HeLa cells. In addition to the human
TRIM proteins most closely related to TRIM5, we studied
TRIM4 and TRIM27 as examples of more distant TRIM
relatives. The FLAG-tagged human TRIM4, TRIM6, TRIM22,
TRIM27 and TRIM34 all colocalized with rhesus monkey
TRIM5α (Figs. 2A and B). In at least some of the cells, these
TRIM proteins were located in the cytoplasm and formed
cytoplasmic bodies. In some of the TRIM22-expressing cells
and most of the TRIM27-expressing cells, these proteins as
well as TRIM5αrh were partly located in the nucleus.
Apparently, the intracellular location of TRIM5αrh can be
influenced by the coexpression of other TRIM proteins.
Similarly, human TRIM5α was shown to colocalize with
Fig. 1. Phylogeny of human TRIM family proteins containing a B30.2(SPRY) domain. A neighbor joining tree based on the amino acid sequences of 38 human TRIM
proteins containing a B30.2(SPRY) domain is shown. Numbers indicate bootstrap proportions after 500 replications. The scale bar represents 0.1 changes per site. The
highlighted TRIM proteins are encoded by human TRIM genes located in the indicated chromosomal clusters.
421X. Li et al. / Virology 360 (2007) 419–433fusion proteins consisting of enhanced green fluorescent
protein (GFP) and the human TRIM proteins listed above
(data not shown).
TRIM proteins form trimers
It has been shown that wild-type TRIM5α proteins from
different primate species form trimers (Mische et al., 2005).
To investigate whether oligomerization is a common feature
of cytoplasmic TRIM family members, cell lysates from HeLa
cell lines stably expressing different TRIM proteins wereincubated with increasing concentrations of the crosslinker
glutaraldehyde and subsequently analyzed by Western blot-
ting. All of the TRIM proteins were crosslinked into gel-
stable complexes with molecular weights of approximately
150–180 kDa, consistent with the formation of trimers (Fig.
3). At high concentrations of the crosslinker, protein bands
with even higher molecular weight (>250 kDa) were also
seen for some TRIM proteins. These species may represent
dimers of trimers. TRIM34 formed distinct high-molecular-
weight complexes even in the absence of glutaraldehyde,
indicating the unusual resistance of these forms to heat and
Fig. 2. Co-localization of rhesus monkey TRIM5α and other TRIM proteins. (A,
B) HeLa cells stably expressing V5-tagged rhesus monkey TRIM5α and FLAG-
tagged human TRIM proteins (or the empty LPCX vector) were fixed and
permeabilized. Cells were stained with anti-V5 antibody conjugated to Cy3 (red)
or an anti-FLAG antibody conjugated to FITC (green). Stained cells were
examined using a confocal fluorescent microscope.
422 X. Li et al. / Virology 360 (2007) 419–433SDS. We conclude that cytoplasmic TRIM proteins are
trimeric.
TRIM5α turns over faster than other related TRIM proteins
Both human and rhesus monkey TRIM5α proteins have short
half-lives in cells stably expressing those proteins (Diaz-Grifferoet al., 2006a). The RING and B-box 2 domains both contribute to
this fast turnover rate. We examined the half-lives of other TRIM
proteins to see whether rapid turnover is a shared feature.
HeLa cell lines stably expressing either C- or N-terminally
tagged TRIM proteins were treated with cycloheximide and
assayed for protein expression at different time points, as
previously described (Diaz-Griffero et al., 2006a). As expected,
TRIM5α almost completely disappeared within 2 h of treatment
(Fig. 4). Of the other TRIM proteins, only TRIM4, which is not
closely related to TRIM5 (26.8% identity), exhibited a rapid
turnover, approximately two-fold slower than that of TRIM5α.
The other TRIM proteins, including TRIM6, TRIM34 and
TRIM22, which are closely related to TRIM5, exhibited half-
lives of at least 5 h. TRIM21 and TRIM22 were very stable
proteins. Of interest, replacement of the rhesus monkey
TRIM5α RING domain with that of TRIM21 results in an
increased half-life (Diaz-Griffero et al., 2006a). Apparently,
features of the TRIM5α RING and B-box 2 domains are
unusual in this subset of TRIM proteins, specifying rapid
turnover.
Effect of TRIM proteins on the efficiency of retroviral infection
To examine the antiviral potential of the human TRIM
proteins chosen for study, Cf2Th canine thymocytes expressing
these proteins were infected with various recombinant retroviral
vectors. A search of the dog genome failed to reveal a TRIM5
ortholog (data not shown). Thus, canine cells are free of potential
complications resulting from interactions of the TRIM proteins
with endogenous TRIM5α. The TRIM proteins were tagged at
the N-terminus with a FLAG epitope. Addition of the FLAG tag
at the N- or C- terminus did not affect the ability, or lack thereof,
of these TRIM proteins to restrict virus infection (data not
shown). The rhesus monkey TRIM5α construct from a previous
study was tagged at the C-terminus with an HA epitope derived
from influenza virus (Stremlau et al., 2004). Some variation in
the steady-state level of expression of these TRIM proteins was
observed on Western blots (Fig. 5A); however, with the
exception of TRIM27, all of the TRIM proteins were expressed
as efficiently as TRIM5αhu. To assess antiretroviral activity, the
Cf2Th stable cell lines were infected with different GFP-
expressing recombinant retroviruses that were pseudotyped with
the vesicular stomatitis virus (VSV) G glycoprotein. The
retroviruses tested were human immunodeficiency virus
(HIV-1), simian immunodeficiency virus of macaques (SIVmac),
simian immunodeficiency virus of African green monkeys
(SIVagm), N-tropic and B-tropic murine leukemia viruses
(N-MLV and B-MLV, respectively), equine infectious anemia
virus (EIAV), feline immunodeficiency virus (FIV), and bovine
immunodeficiency virus (BIV). As expected, rhesus monkey
TRIM5α potently restricted HIV-1, N-MLV, SIVagm, FIV and
EIAV infections, and exerted modest inhibitory activity against
SIVmac infection (Figs. 5B and C). Human TRIM5α potently
blocked N-MLV infection and modestly inhibited HIV-1,
SIVmac, EIAV, FIV and BIV infections. Of the other TRIM
proteins tested, only TRIM34 was associated with any antiviral
activity, modestly inhibiting SIVmac infection; very slight
Fig. 3. Oligomerization of TRIM proteins. Lysates fromHeLa cells stably expressing TRIM proteins were cross-linked with increasing concentrations of glutaraldehyde
(0, 0.2, 0.4, 0.8 and 2.0 mM for TRIM5αhu and TRIM22, and 0, 0.05, 0.1 and 0.2 mM for the other TRIM proteins). The cross-linked products were resolved by SDS-
PAGE and visualized by Western blotting with an anti-FLAG antibody. The position of the molecular weight markers (in kiloDaltons) is indicated on the figure.
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TRIM34-expressing cells. Thus, the human and rhesus monkey
TRIM5α proteins exhibit greater restricting activity against
specific members of this retrovirus panel than the related human
TRIM proteins.Fig. 4. Turnover of TRIM proteins. HeLa cells expressing different FLAG-
tagged TRIM proteins were treated with cycloheximide for a period of 7 h.
Cells were lysed at the indicated time points after the initiation of treatment.
Cell lysates containing equal amounts of total proteins were analyzed by
Western blotting with an anti-FLAG antibody or anti-actin antibody as controls.
Both N- and C-terminally tagged proteins were examined, with comparable
results; only one representative set of results is shown here.Dominant-negative effects of some TRIM proteins on human
and rhesus monkey TRIM5α
The antiviral activities of the TRIM proteins were also
examined in HeLa cells. The steady-state expression levels of
these TRIM proteins in HeLa cells were comparable to those in
Cf2Th cells (data not shown). The potent restricting activity of
rhesus monkey TRIM5α against HIV-1 and N-MLV, and that of
human TRIM5α against N-MLV, were evident in the HeLa cells
(Fig. 6). HIV-1 and N-MLV infections of TRIM34-expressing
HeLa cells were slightly but reproducibly more efficient than
those seen in control cells transduced with the empty LPCX
vector. N-MLV infection was also slightly enhanced by
expression of TRIM6 in the HeLa cells. TRIM6- and
TRIM34-expressing cells exhibited increased susceptibility to
infection by BNBB-MLV compared with control cells trans-
duced with the empty LPCX vector (data not shown). The
BNBB-MLV-GFP vector is identical to B-MLV-GFP except
that residue 110 of the viral capsid has been changed from
glutamic acid to arginine, the amino acid residue found at that
position in the N-MLV capsid protein. This change in the capsid
renders BNBB-MLV-GFP susceptible to restriction mediated by
human TRIM5α (Towers et al., 2000; Perron et al., 2004).
These results suggest that TRIM6 and TRIM34 may exert very
mild dominant-negative effects on the endogenous human
TRIM5α protein in the HeLa cells.
The effect of expression of the human TRIM proteins on the
anti-HIV-1 activity of rhesus monkey TRIM5α was examined.
HeLa cells were stably transduced with an empty LPCX vector
or an LPCX vector expressing FLAG-tagged human TRIM4, 6,
22, 27 or 34. These cells were then transduced with a pLenti
vector expressing V5-tagged TRIM5αrh or with the empty pLenti
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shown in Fig. 7A. The cells were then challenged with
recombinant HIV-1 expressing GFP (Fig. 7B). TRIM5αrh
inhibited HIV-1 infection in all of the cell lines except the cells
coexpressing TRIM34. Apparently, TRIM34 can act as a
dominant-negative inhibitor of TRIM5αrh.
Association of other TRIM proteins with TRIM5α
The colocalization of these TRIM proteins with TRIM5α
and the dominant-negative effects seen in the above assays
suggested that some TRIM relatives might interact withFig. 5. Expression and antiretroviral activity of TRIM family proteins stably express
cells was assessed by Western blotting with antibodies directed against epitope tags. T
the C-terminus; all the other TRIM proteins are FLAG-tagged at the N-termini. As a c
the effects of the TRIM proteins on retroviral infection, Cf2Th cells expressing diff
vector, were incubated with various amounts of recombinant HIV-1, SIVmac, N-MLV
FACS. Ten dose units of HIV-1 or SIVmac correspond to∼3000 cpm reverse transcrip
transcriptase units. (C) Cf2Th cells expressing the different TRIM proteins, or contr
dose of recombinant BIV, EIAV, FIVor SIVagm virus expressing GFP that was sufficie
counted by FACS.TRIM5α. To address this possibility, we coexpressed
TRIM5α and the TRIM proteins in cells and attempted to
coprecipitate the proteins from cell lysates. HeLa cells stably
expressing V5-tagged rhesus monkey TRIM5α from a pLenti
vector were transduced with LPCX retroviral vectors encoding
FLAG-tagged human TRIM proteins. The resulting cell lines
expressed both TRIM5αrh-V5 and FLAG-tagged TRIMhu
proteins (Fig. 8A). Cell lysates were then prepared from these
cell lines and used for immunoprecipitation with anti-V5 and
anti-FLAG antibodies. Human TRIM5α was efficiently co-
immunoprecipitated with rhesus monkey TRIM5α, and vice
versa (Figs. 8B and C). This is consistent with yeast two-hybrided in Cf2Th cells. (A) Expression of TRIM proteins stably expressed in Cf2Th
RIM5αrh carries an HA tag at the C-terminus; TRIM5αhu carries a FLAG tag at
ontrol, the amount of β-actin in the cell lysates was also examined. (B) To assess
erent TRIM proteins, or control Cf2Th cells transduced with the empty LPCX
or B-MLV viruses expressing GFP. Infected GFP-positive cells were counted by
tase units; 100 dose units of N-MLVor B-MLV correspond to∼400 cpm reverse
ol Cf2Th cells transduced with the empty pLPCX vector, were incubated with a
nt to infect 50–80% of the control Cf2Th cells. Infected GFP-positive cells were
Fig. 5 (continued).
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previous co-immunoprecipitation experiments with rhesus
monkey TRIM5α and its derivatives (Javanbakht et al.,
2005). None of the heterologous TRIM proteins interacted
efficiently with TRIM5αrh under the conditions used (Figs. 8B
and C). Only TRIM6 and TRIM34 were very weakly co-
immunoprecipitated with rhesus monkey TRIM5α in both
directions, which may help to explain their mild dominant-Fig. 6. Antiretroviral activity of TRIM family proteins stably expressed in HeLa cells
indicated recombinant viruses were assessed as described in the legend to Fig. 5. Thnegative activities. The weakness of the heterologous interac-
tions supports previous observations made in the yeast two-
hybrid system that TRIM proteins preferentially form homo-
oligomers (Reymond et al., 2001).
To examine whether TRIM5αrh might associate with other
TRIM proteins after synthesis and trimerization, cytosolic
extracts were prepared from 293T cells transiently expressing
V5-tagged TRIM5αrh and from separate cells transiently. The effects of stable TRIM protein expression in HeLa cells on infection of the
e control cells were transduced with the empty LPCX vector.
Fig. 7. Effect of expression of human TRIM proteins on the anti-HIV-1 activity of rhesus monkey TRIM5α. HeLa cells were stably transduced with an empty LPCX
vector or an LPCX vector expressing the indicated FLAG-tagged human TRIM proteins. The cells were then transduced with a pLenti vector expressing V5-tagged
TRIM5αrh or with an empty pLenti vector. (A) Cell lysates were Western blotted (WB) with an anti-FLAG antibody (upper panel), an anti-V5 antibody (middle panel),
or an antibody directed against β-actin (lower panel). (B) The HeLa cells were incubated with different doses of recombinant HIV-1 expressing GFP and pseudotyped
with VSV G glycoprotein. Flow cytometry was used to determine the percentage of GFP-positive cells. The results shown are from a single experiment and are typical
of those obtained in three independent experiments.
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Fig. 8. Co-immunoprecipitation of human TRIM proteins and rhesus TRIM5α. HeLa cells stably expressing both a FLAG-tagged human TRIM protein from an LPCX
vector and V5-tagged rhesus monkey TRIM5α from a pLenti vector were established. As a control, HeLa cells expressing the FLAG-tagged human TRIM proteins but
carrying an empty pLenti vector were established in parallel. (A) To assess the level of expression of the TRIM proteins, cell lysates were analyzed by SDS-PAGE and
Western blotted (WB) with anti-FLAG and anti-V5 antibodies. TRIM34 forms high-molecular-weight aggregates when boiled for 5 min. (B) Immunoprecipitation of
the TRIM5αrh-V5 protein with an anti-V5 antibody was used to detect coprecipitated proteins. The upper panel shows the rhesus monkey TRIM5α protein that was
precipitated by the anti-V5 antibody; the lower panel shows the coprecipitated TRIM proteins that were detected by Western blotting (WB) with an anti-FLAG
antibody (arrow). A faster-migrating non-specific band, which was detected in all the samples, conveniently serves as a loading control. (C) Cell lysates containing
FLAG-tagged TRIM proteins were precipitated with an anti-FLAG antibody. Precipitates were Western blotted with an anti-V5 antibody to detect coprecipitated
TRIM5αrh-V5 protein. The upper panel shows the FLAG-tagged TRIM proteins that were precipitated; the lower panel shows the coprecipitated TRIM5αrh protein.
(D) Cytosolic extracts from 293Tcells transiently expressing TRIM4, 6, 22, 27 or 34 (all tagged with a FLAG peptide) were mixed in a 1:1 ratio with cell extracts from
293T cells transiently expressing TRIM5αrh (tagged with a V5 peptide). The mixtures were Western blotted (WB) with antibodies directed against FLAG, V5 and
β-actin (upper three panels). The mixtures were also used for immunoprecipitation (IP) by an anti-FLAG antibody, or by control Protein A-Sepharose beads only
(Mock). The precipitates were Western blotted with an anti-V5 antibody (bottom two panels). Similar results were obtained in three independent experiments.
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TRIM27 or TRIM34. The cytosolic extracts were mixed in a
1:1 ratio and used for precipitation by the antibody recognizing
the FLAG epitope on the human TRIM proteins. The
precipitates were analyzed by Western blotting with an anti-
V5 antibody to detect any coprecipitated TRIM5αrh. Under
these conditions, TRIM34 and TRIM6 associated with
TRIM5αrh more efficiently than did the other human TRIM
proteins tested (Fig. 8D).
Ability of TRIM proteins to bind HIV-1 capsid preparations
The ability of TRIM5α proteins to bind the assembled
retroviral capsid is thought to be necessary but not sufficientfor the restriction of infection (Diaz-Griffero et al., 2006b;
Stremlau et al., 2006). To examine the ability of the
different TRIM proteins to associate with the HIV-1 capsid,
we used an assay that measures the cosedimentation of
epitope-tagged TRIM proteins with HIV-1 capsid–nucleo-
capsid (CA–NC) complexes that were assembled in vitro
(Stremlau et al., 2006; Li et al., 2006b). Rhesus monkey
TRIM5α associated with the HIV-1 CA–NC complexes that
sedimented through 70% sucrose (Fig. 9A). The human
TRIM6 and TRIM34 proteins also cosedimented with the
HIV-1 CA–NC complexes, whereas the other TRIM proteins
tested did not (Figs. 9A and B and data not shown). The
TRIM5αrh, TRIM6 and TRIM34 proteins did not pellet
through the 70% sucrose cushion in the absence of added
Fig. 9. Ability of TRIM proteins to bind HIV-1 capsid complexes. (A) Cell
lysates of 293T cells transiently transfected with N-terminally FLAG-tagged
TRIM variants were used in the HIV-1 CA–NC binding assay. The top and
middle panels show the amounts of TRIM protein in the input and pellet,
respectively; the bottom panel shows the amount of HIV-1 CA–NC protein that
was pelleted through the 70% sucrose cushion. The variants of TRIM6,
TRIM34 and TRIM5αrh that were studied include the full-length proteins (F),
the RBCC protein (R), and the RBCC-L2 proteins (L). The positions of the
molecular weight markers are indicated on the left side of the gels. (B) TRIM
proteins were examined for the ability to sediment through the 70% sucrose
cushion in the absence and presence of the in vitro assembled HIV-1 capsid
complexes. The upper and lower panels show the amount of TRIM protein in
the input and pellet, respectively, assayed by Western blotting. Mutant TRIM6
RBCC-L2 (6L2) was tested at two different protein concentrations (low and
high) for quantitative comparison. Two other TRIM family proteins (TRIM21
and TRIM22) exhibit no and very weak capsid-binding capabilities,
respectively.
428 X. Li et al. / Virology 360 (2007) 419–433HIV-1 CA–NC complexes (Fig. 9B), indicating the specificity
of the association.
The recognition of HIV-1 capsids by TRIM5αrh is dependent
upon the B30.2(SPRY) domain (Stremlau et al., 2006). To
examine whether the association of TRIM6 and TRIM34 with
the HIV-1 CA–NC complexes is similarly dependent on their
B30.2(SPRY) domains, we created and tested the RBCC and
RBCC-L2 mutants of these proteins in the HIV-1 capsid binding
assay. The RBCC constructs include the RING, B-box 2 and
coiled-coil domains of the proteins; the RBCC-L2 constructs
contain, in addition, the L2 linker located between the coiled-
coil and B30.2(SPRY) domains. As expected, the RBCC and
RBCC-L2 variants of rhesus monkey TRIM5α did not
detectably associate with the HIV-1 CA–NC complexes (lanes
R and L, respectively, in Fig. 9A). The cosedimentation of
TRIM34 with the HIV-1 CA–NC complexes was alsodependent upon the integrity of the B30.2(SPRY) domain
(Fig. 9A). By contrast, the RBCC-L2 variant of TRIM6, but not
the RBCC variant, exhibited efficient association with the HIV-
1 CA–NC complexes (Figs. 9A and B). Thus, the association of
human TRIM34, but not human TRIM6, with the assembled
HIV-1 capsid complexes is dependent upon the B30.2(SPRY)
domain, as is the case for TRIM5αrh.
Analysis of nonsynonymous/synonymous variation in different
TRIM genes
Repeated exposure of a species to rapidly evolving viruses is
expected to exert strong positive selective pressure on elements
of the host immune system that directly interact with viral
components (Haldane, 1949). Analysis of nonsynonymous/
synonymous variation (Ka/Ks ratios) can provide insight into
selection for or against change in the coding capacity of a gene
(Li, 1993). TRIM5 exhibits an unusual pattern of nonsynon-
ymous/synonymous variation. The 5′ portion of TRIM5 has a
low Ka/Ks ratio, indicative of purifying selection. The 3′ end of
TRIM5, which encodes the B30.2(SPRY) domain, exhibits a
high Ka/Ks ratio indicative of positive selection (Liu et al., 2005;
Sawyer et al., 2005; Song et al., 2005b). To investigate potential
selection operating on related TRIM genes, we calculated the
Ka/Ks ratios at various codon positions for pairwise comparison
of TRIM5, TRIM6, TRIM22 and TRIM34 cDNAs from a
hominoid (human), an Old World monkey (baboon), a New
World monkey (marmoset) and a prosimian primate (lemur,
only for TRIM6) (Fig. 10). The Ka/Ks ratios for TRIM6 are well
below 1 throughout the coding sequence, suggesting that
purifying selection has operated on TRIM6 to preserve the
amino acid sequences. For TRIM22 and TRIM34, the Ka/Ks
ratios average around 1; apparently, these genes have undergone
neutral evolution.
Discussion
In addition to the domain structure common to all TRIM
proteins, TRIM5α shares several properties with the other TRIM
proteins examined here. At least some of these TRIM proteins
(TRIM6, TRIM34 and TRIM22) are encoded by TRIM5
paralogs that, along with TRIM5, comprise a cluster of genes
on human chromosome 11p15.4. All of the human TRIM
proteins examined herein are trimeric. Trimerization, which
involves TRIM5 sequences in the coiled coil and adjacent
regions, is important for the antiretroviral activity of TRIM5α
(Javanbakht et al., 2006). Trimerization occurs preferentially in
an homologous fashion (Reymond et al., 2001); however, we did
observe very weak heterologous association between rhesus
monkey TRIM5α and either human TRIM6 or human TRIM34.
This weak association might contribute to some of the mild
dominant-negative effects observed for TRIM6 and TRIM34
with respect to TRIM5α antiretroviral activity. The RBCC
domains of related TRIM proteins, TRIM6 and TRIM34, can
functionally substitute for those of rhesus monkey TRIM5α (Li
et al., 2006a). Heterologous RBCC domains have recently been
reported to allow the HIV-1-restricting ability of TRIMCyp, an
Fig. 10. Nonsynonymous/synonymous ratios (Ka/Ks) for pairwise comparisons of TRIM cDNAs. The plots show the Ka/Ks ratios at various codon positions for
pairwise comparisons of human (H), baboon (B), marmoset (M) and lemur (L) TRIM cDNAs. The Ka/Ks ratios, calculated by a previously described method (Li,
1993), were estimated as rolling averages for a window of 150 codons.
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domains fused with cyclophilin A (Nisole et al., 2004; Sayah et
al., 2004; Zhang et al., 2006).
Like TRIM5α, the TRIM relatives studied herein localize
in the cytoplasm and, when overexpressed, form cytoplasmic
bodies or speckles. Cytoplasmic localization is likely impor-
tant for antiretroviral activity, as TRIM5α and TRIMCyp have
been shown to exert their inhibitory effects on the retroviral
capsid within the first hour following virus entry (Perez-
Caballero et al., 2005; Yap et al., 2006; Diaz-Griffero et al.,
2006b). The association of TRIM5α and TRIMCyp with
cytoplasmic bodies is not necessary for their antiretroviral
activity (Song et al., 2005a; Perez-Caballero et al., 2005),
although other aspects of the tendency for self-aggregation
that TRIM proteins exhibit may contribute in as-yet-unknown
ways to the antiviral effect. At a minimum, the properties of
trimerization and cytosolic location would be conducive to the
evolution of host factors that interact with incoming retroviral
capsids, which exhibit trimeric pseudosymmetry (Li et al.,
2000).
TRIM5α exhibits several features that are unique among
the primate TRIM proteins examined. Most importantly, only
TRIM5α exhibited potent inhibitory activity against the
retroviruses tested. Weak activity against some retroviruses,
such as SIVmac, was observed for human TRIM34, consistent
with a recent report (Zhang et al., 2006). The biological
relevance of retroviral restriction by TRIM34 is uncertain.
TRIM34 exhibits a high propensity for self-aggregation and
may, when overexpressed, be prone to associate with other
moieties in a less specific fashion. TRIM34, and TRIM6 as
well, were able to associate efficiently with the HIV-1 capsid;however, only the association of TRIM34 with the HIV-1
capsid appeared to require its B30.2(SPRY) domain. The
mechanistic basis, specificity and biological relevance of the
TRIM6 and TRIM34 association with the HIV-1 capsid will
require additional investigation. Capsid association could
contribute to the weak dominant-negative activities detected
for these two TRIM proteins. The ability of a TRIM6 and
TRIM34 ancestor to associate with viral capsids might have
provided an evolutionary starting point for the specific binding
of TRIM5-like paralogs to retroviral capsids.
Analysis of the nonsynonymous/synonymous changes in
this group of TRIM genes revealed that the high Ka/Ks ratio
that characterizes the B30.2(SPRY) domain-coding portion of
TRIM5 is not evident in the other TRIM genes examined. Host
components of the innate or adaptive antiviral immune
response that directly interact with evolutionarily labile viral
targets would be expected to exhibit such evidence of positive
selection (Haldane, 1949). The TRIM genes most closely
related to TRIM5 had Ka/Ks ratios less than or equal to 1,
indicative of purifying or neutral selection, respectively. This
observation suggests that, if TRIM6, TRIM34 and/or TRIM22
are involved in antiviral defenses, they probably do not
directly recognize a changeable viral component. A study of
the evolution of the APOBEC family of cytidine deaminases
also found that certain members of the family known to
possess antiretroviral activity were under strong positive
selection, whereas other members of the family were under
purifying selection (Sawyer et al., 2004). Thus, although
certain structural or biochemical properties of the APOBEC
and TRIM protein family are conducive to the evolution of
antiviral factors, only some family members may be selected
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viruses.
At least in the context of the overexpression systems studied
herein, TRIM5α turned over more rapidly than any of the
closely related TRIM proteins. Only the distantly related
TRIM4 protein exhibited a half-life that approached the short
half-life of TRIM5α. The TRIM5α RING and B-box 2 domains
both contribute to the rapid turnover of this protein (Diaz-
Griffero et al., 2006a). Studies of a chimeric protein in which
the TRIM5αrh RING domain is replaced by that of the more
stable TRIM21 indicated that rapid turnover is not necessary for
antiviral function (Diaz-Griffero et al., 2006a). However, rapid
turnover of TRIM5α may minimize any detrimental effects of
this protein on cells when viruses are not present, and also allow
rapid upregulation of TRIM5α expression when virus infection
is detected.
The TRIM5 relatives likely arose by duplication events
involving ancestral TRIM genes. Gene duplication lessens the
selective constraints on one copy of the gene, thus allowing the
evolution of new functions while the other copy continues to
perform the essential original function (Hancock, 2005). The
signs of stringent purifying selection in TRIM6 suggest the
probable functional importance of its protein product. Overall,
TRIM22 and TRIM34 appear to be under more relaxed
selective constraints. Understanding the natural cellular func-
tion of these TRIM proteins would be of interest in its own
right and might provide additional insight into TRIM5α
function.
Materials and methods
Phylogenetic analyses
The amino acid sequences of human TRIM proteins that
contain a B30.2(SPRY) domain were extracted from the
Ensembl database (http://www.ensembl.org/). Amino acid
alignments were constructed using the online MAFFT v5.8
server (http://timpani.genome.ad.jp/%7Emafft/server/) with the
E-INS-i iterative refinement method (Katoh et al., 2005).
Phylogenetic analysis was performed using PAUP v4.0b10
(Swofford, 2002). A neighbor joining bootstrap analysis was
performed on the amino acid alignment using the BioNJ setting
(Gascuel, 1997) and 500 replications.
Because the B30.2(SPRY) domain may be a hotspot for
positive selection (Sawyer et al., 2005; Si et al., 2006; Song et
al., 2005b), additional analyses similar to those described above
were performed after removing the B30.2(SPRY) domain (as
defined in Song et al., 2005b). The B30.2(SPRY)-deleted TRIM
analysis was performed to reduce the possibility of highly
variable or convergent residues affecting the phylogenetic
reconstruction.
Nonsynonymous/synonymous variation
The nonsynonymous/synonymous (Ka/Ks) ratios at various
codon positions for pairwise comparisons of TRIM cDNAs
were calculated by the method of Li (Li, 1993). The Ka/Ks ratiowas estimated as a rolling average for a window of 150 codons,
with the center of the window being moved codon-by-codon to
produce a plot showing local variation in the degree of sequence
conservation.
Creation of cells stably expressing TRIM family proteins
The cDNAs encoding human TRIM4β (NM_033091),
TRIM6 isoform 2 (NM_058166), TRIM21 (NM_003141),
TRIM22 (NM_006074), TRIM27 (NM_006510) and TRIM34
isoform 1 (NM_021616) were obtained either from a human
kidney cDNA library by PCR (Polymerase Chain Reaction) or
purchased from Open Biosystems. A sequence encoding the
FLAG epitope tag (DYKDDDDK) was inserted at the 5′ end of
the cDNAs, which were subsequently cloned into the pLPCX
retroviral vectors using the ClaI and EcoRI/XhoI sites.
Recombinant viruses were produced in 293FT cells (Invitrogen)
by cotransfecting the pLPCX plasmids expressing the different
TRIM proteins with the pVPack-GP and pVPack-VSV-G
packaging plasmids (Stratagene). The pVPack-VSV-G plasmid
encodes the vesicular stomatitis virus (VSV) G envelope
glycoprotein, which allows efficient entry into a wide range
of vertebrate cells (Yee et al., 1994). The resulting virus
particles were used to transduce 2×105 Cf2Th cells or HeLa
cells in six-well plates. Cf2Th cells are canine thymocytes, and
HeLa are human epithelial cells. Cf2Th and HeLa cells were
then selected in 5 μg/ml and 1 μg/ml puromycin (Sigma),
respectively.
To create cell lines coexpressing two TRIM proteins,
blasticidin-resistant HeLa cells stably expressing rhesus
TRIM5α-V5 from a pLenti vector were first made using the
Viral Power system (Invitrogen). These cells were then
transduced as described above with the pLPCX retroviral
vectors encoding different FLAG-tagged TRIM proteins and
selected in puromycin.
Immunoblotting
Cf2Th or HeLa cells stably expressing the transduced
proteins were lysed with phosphate-buffered saline (2.7 mM
KCl, 1.5 mM KH2PO4, 138 mM NaCl, 8 mM Na2PO4)
containing 1% NP40 and protease inhibitor cocktail (Roche).
The lysates were resolved by SDS-PAGE and Western blotted
with horseradish peroxidase-conjugated anti-FLAG M2 anti-
body (Sigma) and anti-β-actin antibody (Sigma).
Infection with viruses expressing GFP
Recombinant HIV-1, SIVmac, N-MLV, B-MLV, SIVagm,
FIV, BIV and EIAV viruses expressing green fluorescent
protein (GFP) were made as previously described (Perron et
al., 2004; Stremlau et al., 2004; Si et al., 2006). For infection,
3×104 cells were seeded in 24-well plates and incubated with
the viruses for 60 h. Cells were then washed with PBS, fixed
with 3.7% formaldehyde and subjected to fluorescence-
activated cell sorting (FACS) analysis with a FACScan
(Becton Dickinson).
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Cell lysates prepared in 1% NP40/PBS/protease inhibitor
cocktail were incubated with varying concentrations (final
concentration: 0, 0.2, 0.4, 0.8 and 2.0 mM) of glutaraldehyde
(Sigma) at room temperature for 5 min, followed by adding
excess glycine to quench the reaction. The crosslinked lysates
were then subjected to SDS-PAGE and Western blotted with
HRP-conjugated anti-FLAG antibody (Sigma).
Subcellular localization using immunofluorescence confocal
microscopy
HeLa cells stably coexpressing human TRIM4, 6, 22, 27 or
34 and rhesus monkey TRIM5α were grown overnight on 12-
mm-diameter coverslips and fixed in 3.9% paraformaldehyde
(Sigma) in phosphate-buffered saline (PBS; Cellgro) for 30 min.
Cells were washed in PBS and permeabilized with 0.05%
saponin for 30 min. Samples were blocked with 10% donkey
serum (Dako, Carpinteria, CA) for 30 min, and incubated for 1 h
with antibodies. The anti-V5-Cy3 antibody (Sigma) was used to
stain V5-tagged TRIM5αrh and anti-FLAG-FITC antibody
(Sigma) was used to stain the FLAG-tagged human TRIM
proteins (TRIM4, 6, 22, 27 and 34). Subsequently, samples
were mounted for fluorescence microscopy by using the
ProLong Antifade Kit (Invitrogen). Images were obtained
with a BioRad Radiance 2000 laser scanning confocal
microscope with Nikon 60× N.A.1.4 optics.
To study localization of GFP-TRIM fusion proteins and
human TRIM5α, HeLa cells stably expressing HA-tagged
human TRIM5α in 12-well plates were transfected with 1 μg of
GFP-TRIM fusion constructs for 24 h using Gene Porter 2
(GTS, San Diego), and then subcultured on 8-well chamber
slides. Twenty-four hours later, the cells were fixed, permea-
bilized, and incubated with rat anti-HA 3F10 antibody (1:200,
Roche) followed by secondary anti-rat IgG conjugated with
TRITC (1:200, Santa Cruz). The processed cells were analyzed
using a confocal microscope (Nikon Eclipse E800) with laser
(Bio-Rad MRC 1024), and the images were obtained using Bio-
Rad Lasersharp 2000 software.
Co-immunoprecipitation
HeLa cells stably expressing both pLenti vector/rhesus
TRIM5α-V5 and pLPCX vector/human FLAG-TRIM proteins
from nearly confluent 100-mm plates were lysed in 1 ml of lysis
buffer (1% NP40/PBS/protease inhibitor cocktail). The lysates
were cleared of insoluble materials and aggregates by
centrifugation at 100,000×g for 30 min. To minimize non-
specific interaction with Protein A-Sepharose beads (Pharma-
cia), 0.5 ml of supernatant were first incubated with 20 μl beads
(packed volume) for 4 h at 4 °C. The precleared lysates were
then mixed with 20 μl fresh beads and 1 μl of either anti-V5
(Invitrogen) or anti-FLAG (Sigma) antibodies (∼1.3 μg and
4.3 μg, respectively) overnight at 4 °C. The immunoprecipitates
were washed three times with buffer I (300 mM NaCl, 50 mM
Tris–HCl, 1% NP40) at 4 °C for 10 min each on a rocker andonce with buffer II (150 mM NaCl, 10 mM Tris–HCl) for
10 min at 4 °C. The beads were then treated with 2× SDS
sample buffer (125 mM Tris–HCl, 3% SDS, 16.7% glycerol,
3% β-mercaptoethanol, 0.01% bromophenol blue) and boiled
for 5 min to release the precipitated proteins. Supernatants were
analyzed by SDS-PAGE and Western blotting with HRP-
conjugated anti-V5 antibody (1:5000, Invitrogen) or anti-FLAG
antibody (1:500, Sigma).
To examine the ability of mature TRIM proteins to associate
with TRIM5α, TRIM proteins (TRIM4, 6, 22, 27 and 34)
tagged with a C-terminal FLAG peptide were transiently
expressed in 293T cells by using Lipofectamine 2000 (Invitro-
gen). In a separate plate of 293T cells, TRIM5αrh tagged with a
C-terminal V5 peptide was transiently expressed. Cytosolic
extracts were prepared by using a Dounce homogenizer (10
strokes) in buffer containing 100 mM KC1, 20 mM Tris–HCl
pH 7.5, 5% glycerol and 0.5 mM DTT. Samples were
centrifuged at 3000 rpm to remove nuclei and cell debris.
Each of the TRIM protein-containing extracts was mixed with
TRIM5αrh-containing extracts in a 1:1 ratio. Mixtures were
immunoprecipitated using an anti-FLAG monoclonal antibody
(Sigma) at 4 °C for 3 h. Immunoprecipitates were washed 10
times using lysis buffer. Mixtures and precipitates were blotted
using anti-FLAG, anti-V5 (Invitrogen) and anti-β-actin anti-
bodies (Sigma).
The turn-over rate of TRIM proteins
HeLa cells expressing different TRIM proteins were seeded
in 6-well plates 1 day prior to the experiment. When cells
achieved 40–60% confluency, cycloheximide at 100 μg/ml
(Sigma) was added to block protein synthesis. Treated cells
were lysed at different time points and cell lysates containing
equal amount of total proteins were subjected to SDS-PAGE
and Western blotting analysis.
HIV-1 capsid-binding assay
Purification of recombinant HIV-1 capsid–nucleocapsid
(CA–NC) protein from Escherichia coli was carried out as
previously described (Ganser et al., 1999). High-molecular-
weight HIV-1 capsid complexes were assembled using 300 μM
CA–NC protein and 60 μM (TG)50 DNA oligonucleotide in a
volume of 100 μl of 50 mM Tris–HCl (pH 8.0) and 500 mM
NaCl. The reaction was allowed to proceed overnight at 4 °C as
previously described (Ganser et al., 1999). The assembled CA–
NC complexes were stored at 4 °C until needed.
For a source of TRIM5 protein, 293T cells seeded in a six-
well dish were transfected with amounts of pLPCX plasmids to
produce roughly equivalent levels of TRIM protein expression,
according to the manufacturer's protocol (Effectene, Qiagen).
Forty-eight hours later, the cells were harvested in phosphate-
buffered saline containing 5 mM EDTA and resuspended in
270 μl of hypotonic lysis buffer (10 mM Tris, pH 7.4, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT). The cells were lysed by
freeze–thawing and the cell debris was removed by centrifuga-
tion at 4 °C for 10 min at maximum speed (14,000×g) in an
432 X. Li et al. / Virology 360 (2007) 419–433Eppendorf microcentrifuge. Two hundred thirty microliters of
the cleared cell lysate was combined with 5 μl of HIV-1 CA–
NC complexes from the assembly reaction mixture, and the
concentration of salt was adjusted to 150 mM by adding 10×
PBS buffer. The mixture was incubated for 1 h at room
temperature with gentle rocking. After incubation, 20 μl of the
mixture was assayed for input protein amount; the remainder
was layered onto a 3.5-ml 70% sucrose cushion (prepared in 1×
phosphate-buffered saline and 0.5 mM DTT) and centrifuged at
110,000×g for 1 h at 4 °C in a Beckman SW55Ti rotor. The
pellet was resuspended in 80 μl of 1× sodium dodecyl sulfate
(SDS) sample buffer and subjected to SDS-polyacrylamide gel
electrophoresis and Western blotting for TRIM proteins and
HIV-1 p24 capsid protein, as described (Stremlau et al., 2006; Li
et al., 2006b).
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